Christina Matheny

2.0k total citations
29 papers, 1.2k citations indexed

About

Christina Matheny is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christina Matheny has authored 29 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christina Matheny's work include Cancer Immunotherapy and Biomarkers (13 papers), Lung Cancer Treatments and Mutations (6 papers) and Acute Myeloid Leukemia Research (5 papers). Christina Matheny is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Lung Cancer Treatments and Mutations (6 papers) and Acute Myeloid Leukemia Research (5 papers). Christina Matheny collaborates with scholars based in United States, France and South Korea. Christina Matheny's co-authors include Michael L. Cleary, Masayuki Iwasaki, Nancy A. Speck, Daniela Witten, Howard Y. Chang, Achim Rittmeyer, Gary J. Spencer, Tim C. P. Somervaille, James R. Downing and John L. Rinn and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

Christina Matheny

27 papers receiving 1.2k citations

Peers

Countries citing papers authored by Christina Matheny

Since Specialization

Citations

This map shows the geographic impact of Christina Matheny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christina Matheny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christina Matheny more than expected).

Fields of papers citing papers by Christina Matheny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christina Matheny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christina Matheny. The network helps show where Christina Matheny may publish in the future.

Co-authorship network of co-authors of Christina Matheny

This figure shows the co-authorship network connecting the top 25 collaborators of Christina Matheny. A scholar is included among the top collaborators of Christina Matheny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christina Matheny. Christina Matheny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1348MO SKYSCRAPER-09: Phase II, randomised study of tiragolumab (tira) + atezolizumab (atezo) and atezo + placebo (pbo) as first-line (1L) treatment in patients (pts) with recurrent/metastatic PD-L1+ squamous cell carcinoma of the head and neck (R/M SCCHN) 2025 ·Annals of Oncology ·Amanda Psyrri, Christophe Le Tourneau, (unknown), Arunee Dechaphunkul, (unknown), Deborah Jean Lee Wong, SH Lee, Nuttapong Ngamphaiboon, (unknown), Melissa L. Johnson, (unknown), D. K. Bradley, Tien Hoang, (unknown), Christina Matheny, (unknown), (unknown), Yongmin Yan, (unknown)	0
2	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial 2021 ·Clinical Lung Cancer ·Shirish M. Gadgeel, Fred R. Hirsch, Keith M. Kerr, Fabrice Barlési, Keunchil Park, Achim Rittmeyer, Wei Zou, (unknown), Hartmut Koeppen, Sarah Paul, David S. Shames, Jing Yi, Christina Matheny, Marcus Ballinger, Mark L. McCleland, David R. Gandara	13
3	1271P 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC 2020 ·Annals of Oncology ·Julien Mazières, Achim Rittmeyer, Shirish M. Gadgeel, Toyoaki Hida, David R. Gandara, Diego Cortinovis, Fabrice Barlési, (unknown), Christina Matheny, M. Ballinger, K Park	0
4	Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials 2020 ·Journal of Thoracic Oncology ·Julien Mazières, Achim Rittmeyer, Shirish M. Gadgeel, Toyoaki Hida, David R. Gandara, Diego Cortinovis, Fabrice Barlési, Wei Yu, Christina Matheny, Marcus Ballinger, Keunchil Park	112
5	Abstract CT123: IMvoke010: Randomized Phase III study of atezolizumab as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN) 2019 ·Cancer Research ·Deborah Jean Lee Wong, Jérôme Fayette, (unknown), Matthew Kowgier, Ezra E.W. Cohen, (unknown), Arunee Dechaphunkul, Kumar Prabhash, J.L. Geiger, (unknown), Henning Schäfer, Christina Matheny, Fairooz F. Kabbinavar, Alan Sandler, David Raben, Robert I. Haddad	6
6	IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN) 2018 ·Annals of Oncology ·Robert I. Haddad, Deborah J. Wong, Ye Guo, Jérôme Fayette, Ezra E.W. Cohen, Matthew Kowgier, A. Sandler, Christina Matheny, Fairooz F. Kabbinavar, David Raben	17
7	Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study 2018 ·European Journal of Cancer ·Joachim von Pawel, Rodolfo Bordoni, Miyako Satouchi, Louis Fehrenbacher, Manuel Cobo, Ji‐Youn Han, Toyoaki Hida, Denis Moro‐Sibilot, Paul Conkling, David R. Gandara, Achim Rittmeyer, (unknown), Weiguang Yu, Christina Matheny, Hina Patel, Alan Sandler, M. Ballinger, Marcin Kowanetz, (unknown)	79
8	P1.04-33 Retrospective Descriptive Analysis of Metformin with Atezolizumab in Advanced Non-Small Cell Lung Cancer in The OAK Trial 2018 ·Journal of Thoracic Oncology ·Richard J. Pietras, Haipeng Xu, Xiao Hu, Christina Matheny, A. Sandler, Manish R. Patel	8
9	Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study 2018 ·Journal of Thoracic Oncology ·David R. Gandara, Joachim von Pawel, Julien Mazières, Richard Sullivan, Åslaug Helland, Ji‐Youn Han, Santiago Ponce Aix, Achim Rittmeyer, Fabrice Barlési, Toshio Kubo, Keunchil Park, Jerome H. Goldschmidt, Mayank Gandhi, Cindy Yun, Wei Yu, Christina Matheny, Pei He, Alan Sandler, Marcus Ballinger, Louis Fehrenbacher	105
10	Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer 2018 ·Clinical Lung Cancer ·Rodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, Diego Cortinovis, Thomas Karagiannis, Marcus Ballinger, Alan Sandler, Wei Yu, Pei He, Christina Matheny, Federico Felizzi, Achim Rittmeyer	54
11	Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study. 2017 ·Journal of Clinical Oncology ·David R. Gandara, Joachim von Pawel, (unknown), Åslaug Helland, Ji‐Youn Han, Santiago Ponce Aix, Achim Rittmeyer, Fabrice Barlési, Toshio Kubo, Keunchil Park, Jerome H. Goldschmidt, Mayank Gandhi, Cindy Yun, Wei Yu, Christina Matheny, Pei He, Alan N. Sandler, Marcus Ballinger, Louis Fehrenbacher	14
12	Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens 2013 ·Chemistry & Biology ·Christina Matheny, Michael C. Wei, Michael C. Bassik, (unknown), Martin Kampmann, Masayuki Iwasaki, Obdulio Piloto, David E. Solow-Cordero, Donna M. Bouley, Rachel E. Rau, Patrick A. Brown, Michael T. McManus, Jonathan S. Weissman, Michael L. Cleary	57
13	Next-Generation NAMPT Inhibitors For ALL Identified By Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens 2013 ·Blood ·Michael C. Wei, Christina Matheny, Michael C. Bassik, (unknown), Martin Kampmann, Masayuki Iwasaki, Obdulio Piloto, David E. Solow-Cordero, Donna M. Bouley, Rachel E. Rau, Patrick A. Brown, Michael T. McManus, Jonathan S. Weissman, Michael L. Cleary	1
14	GSK-3 Promotes Conditional Association of CREB and Its Coactivators with MEIS1 to Facilitate HOX-Mediated Transcription and Oncogenesis 2010 ·Cancer Cell ·Zhong Wang, Masayuki Iwasaki, Francesca Ficara, Chenwei Lin, Christina Matheny, Stephen H.K. Wong, Kevin S. Smith, Michael L. Cleary	98
15	Hierarchical Maintenance of MLL Myeloid Leukemia Stem Cells Employs a Transcriptional Program Shared with Embryonic Rather Than Adult Stem Cells 2009 ·Cell stem cell ·Tim C. P. Somervaille, Christina Matheny, Gary J. Spencer, Masayuki Iwasaki, John L. Rinn, Daniela Witten, Howard Y. Chang, Sheila Shurtleff, James R. Downing, Michael L. Cleary	263
16	Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant‐negative, or hypomorphic alleles 2007 ·The EMBO Journal ·Christina Matheny, (unknown), Patrick R. Cushing, Yunpeng Zhou, Takeshi Corpora, Michael C. Regan, Miki Newman, Liya Roudaia, Caroline L. Speck, Ting-Lei Gu, Stephen M. Griffey, John H. Bushweller, Nancy A. Speck	85
17	Runx1 Is Expressed in Adult Mouse Hematopoietic Stem Cells and Differentiating Myeloid and Lymphoid Cells, But Not in Maturing Erythroid Cells 2004 ·Stem Cells ·Trista E. North, Terryl Stacy, Christina Matheny, Nancy A. Speck, Marella de Bruijn	110
18	Biochemical and In Vivo Characterization of Amino Acid Substitutions in the Runx1 (AML1) Runt Domain Found in FPD/AML, AML M0, and Cleidocranial Dysplasia (CCD) Patients. 2004 ·Blood ·Christina Matheny, Takeshi Corpora, (unknown), Ting‐Lei Gu, John H. Bushweller, Nancy A. Speck	2
19	Energetic Contribution of Residues in the Runx1 Runt Domain to DNA Binding 2003 ·Journal of Biological Chemistry ·Zhe Li, Jiangli Yan, Christina Matheny, Takeshi Corpora, Jerónimo Bravo, Alan J. Warren, John H. Bushweller, Nancy A. Speck	36
20	The nuclear localization signal of NGFI-A is located within the zinc finger DNA binding domain. 1994 ·Journal of Biological Chemistry ·Christina Matheny, Mark L. Day, Jeffrey Milbrandt	70

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact